The Foundation for the National Institutes of Health Biomarkers Consortium: Past Accomplishments and New Strategic Direction

The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) is a public–private partnership that aims to facilitate drug development with biomarkers across a range of therapeutic areas. The BC is organized to address specific precompetitive biomarker projects, giving participating stakeholders a role in the design and conduct of projects and making the results freely public. Ultimately, the goals of the BC are to accelerate the development of new medicines, inform regulatory decision making, and improve patient care. Here, we describe how the BC works and briefly highlight its accomplishments. The BC has had many notable successful biomarker projects in the past 12 years, including I‐SPY2, which has improved clinical trials and biomarker use for breast cancer, and an evidentiary framework for biomarker qualification. Recently, the BC has undergone a strategic expansion of its scope to include related drug development tools along the lines of the Biomarkers, Endpoints, and other Tools (BEST) resource.

[1]  T. Welte,et al.  Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. , 2010, American journal of respiratory and critical care medicine.

[2]  D. Burstein,et al.  A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials. , 2010, Current drug targets.

[3]  Chris Leptak,et al.  What evidence do we need for biomarker qualification? , 2017, Science Translational Medicine.

[4]  J. Rex,et al.  Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Bernadette A. Thomas,et al.  Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[6]  Sanjay Kaul,et al.  Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials , 2006, Annals of Internal Medicine.

[7]  Bernadette A. Thomas,et al.  Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[8]  Maren S Fragala,et al.  The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.

[9]  Sujoy Ghosh,et al.  The Biomarkers Consortium: Practice and Pitfalls of Open‐Source Precompetitive Collaboration , 2010, Clinical pharmacology and therapeutics.

[10]  J. Powers.  Increasing the efficiency of clinical trials of antimicrobials: the scientific basis of substantial evidence of effectiveness of drugs. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  L. Burke,et al.  A collaborative model for endpoint development for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  J. Buckwalter,et al.  Recommendations of the OARSI FDA Osteoarthritis Devices Working Group. , 2011, Osteoarthritis and cartilage.

[13]  J. Powers,et al.  Developing Outcomes Assessments as Endpoints for Registrational Clinical Trials of Antibacterial Drugs: 2015 Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  David Wholley,et al.  The Biomarkers Consortium , 2014, Nature Reviews Drug Discovery.

[15]  T. Fleming,et al.  Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia , 2019, The Journal of infectious diseases.

[16]  T. Fleming,et al.  Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Andrew W. Lo,et al.  Re-inventing drug development: A case study of the I-SPY 2 breast cancer clinical trials program. , 2017, Contemporary clinical trials.

[18]  G. Lavezzari,et al.  Industry perspectives on biomarker qualification , 2015, Clinical pharmacology and therapeutics.

[19]  Eric P. Winer,et al.  I-SPY 2--Toward More Rapid Progress in Breast Cancer Treatment. , 2016, The New England journal of medicine.

[20]  J. Powers,et al.  Patient-Reported Outcome Assessments as Endpoints in Studies in Infectious Diseases. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  M. Visser,et al.  Consequences of sarcopenia. , 2011, Clinics in geriatric medicine.

[22]  M. Nevitt,et al.  Biomarkers for osteoarthritis: current position and steps towards further validation. , 2014, Best practice & research. Clinical rheumatology.